Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
This article was originally published in The Pink Sheet Daily
Executive Summary
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
You may also be interested in...
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
Taking Stock Of Qiagen
Since its acquisition of Digene in 2007, Qiagen's business mix has shifted significantly towards molecular diagnostics even as the company remains true to its founding premise of making things simpler for customers. It has broadened its skill set in nucleic acid analysis with multiple acquired and licensed technologies for platform development while focusing on high volume tests in women's health and infectious diseases and new ties with pharma. Expect its acquisition pattern to continue.